NCT05357950已完成2 期
A Phase IIb, Randomized, Multi-Center, Multinational, Prospective, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 69
- 试验地点
- 4
- 主要终点
- Number of subjects who discontinued treatment prematurely
研究概览
简要总结
69 subjects with ALS will be enrolled in the study and randomized at a 2:1 ratio to receive the study drug or placebo tablets. Randomization sequences will be in random block sizes and stratified for ENCALS risk category [high risk ≥ -4.5 vs. low risk < -4.5], and for background ALS treatment (riluzole and/or edaravone and/or sodium phenylbutyrate and/or taurursodiol) vs. no background ALS treatment.
All subjects will be administered the drug/placebo twice daily (BID), two tablets each time, for 6 months. Subjects will be allowed to receive standard of care (SOC) treatment of approved products (i.e., riluzole and edaravone). Additionally, subjects will be allowed to receive treatment with off-label sodium phenylbutyrate and taurursodiol, which are accepted for ALS treatment.
Subjects will be evaluated every 2 months for safety, tolerability (adverse events, safety laboratory, vital signs, ECG, withdrawal rates and reasons) and efficacy (e.g. biomarkers, clinical outcomes (ALSFRS-R and SVC, quality of life and survival).
All subjects who complete the 6 months dosing will be switched to the active arm for a 12-month open label extension (OLE).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to comprehend and willing to sign an informed consent form (ICF)
- •Males or females between the ages of 18 and 75 years of age, inclusive
- •Diagnosis of familial or sporadic ALS (defined as meeting the laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the Gold Coast criteria)
- •Disease duration after first symptom (muscle weakness) less than 30 months prior to screening
- •Pre-enrollment ALSFRS-R slope from disease onset ≥ 0.3 points per month
- •ALSFRS-R at screening ≥ 25
- •Item 3 (swallowing) in ALSFRS-R ≥ 3
- •Subjects may be treated in parallel with riluzole and/or edaravone and/or sodium phenylbutyrate and/or taurursodiol; 60 days of stable use prior to enrollment is required
- •Upright slow vital capacity (SVC) ≥ 60% of predicted for age, height, weight and sex at screening according to the GLI-2012
- •18 < BMI < 30
- •A caregiver (if one is needed)
- •Female subjects must be post-menopausal (≥ 1 year) OR sterilized, OR if of childbearing potential (i.e., females who have had their first period unless they are anatomically or physiologically incapable to become pregnant), must have a negative pregnancy test, and agree to use contraceptive drugs or devices (e.g., diaphragm plus spermicide, or oral contraceptives) for the duration of the study and 10 weeks after the last treatment dose AND require male partners to use a condom during sexual intercourse
排除标准
- •A past history of adverse reaction/hypersensitivity to either NSAIDs, celecoxib or fluoroquinolones, ciprofloxacin
- •Any known clinically significant abnormal gastric mucosal erosion, ulcer or tumor or/and GI disorder and/or bariatric surgery
- •Known history of clinically significant impairment of renal function (creatinine ≥ 1.5)
- •Known or suspected symptomatic congestive heart and/or coronary heart disease, previous history of myocardial infarction, uncontrolled arterial hypertension, or rhythm abnormalities requiring permanent treatment
- •Known history of QT/QTc prolongation, Torsade de pointes (TdP) (e.g. heart failure, hypokalemia, family history of Long QT syndrome) and the use of concomitant medications that prolong the QT/QTc interval
- •Known or suspected diagnosis or family history of epilepsy in first degree relatives
- •Known predisposition to tendinitis
- •Known or suspected to be a poor CYP2C9 metabolizers who also uses pharmacologic agents (prescription or over-the-counter) or herbal products known or suspected to induce or inhibit CYP2C9 within 30 days before enrollment
- •Tracheostomy or percutaneous gastrostomy use
- •Presence at screening of any medically significant cardiac, pulmonary, musculoskeletal, or psychiatric illness that might interfere with the subject's ability to comply with study procedures or that might confound the interpretation of clinical safety data, including, but not limited to:
- •Mean systolic blood pressure >160 mm Hg and/or mean diastolic blood pressure >100 mm Hg (measurements taken after a few minutes rest) that persist on 3 successive measurements taken at least 2 minutes apart
- •NYHA Class II or greater congestive heart failure
- •Chronic obstructive pulmonary disease or asthma requiring daily use of bronchodilator medications
- •Poorly controlled or brittle diabetes mellitus
- •Cognitive impairment, related to ALS or otherwise, sufficient to impair subject's ability to understand and/or comply with study procedures and provide informed consent
- •Subject who is treated with chronic aspirin or NSAIDs and is at risk if stopped. Clopidogrel is allowed and can replace Aspirin.
- •Any contraindication for ciprofloxacin and celecoxib according to the current prescribing information.
- •Female who is pregnant or breastfeeding or with intention of becoming pregnant during the course of the study.
- •Any impairment or social circumstance that, in the opinion of the Investigator, would render the subject not suitable to participate in the study.
- •Subject, or subject's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study.
- •Subject is participating in (or plans to participate in) any other investigational drug trial, or plans to be exposed to any other investigational agent, device and/or procedure, from 30 days prior to Screening through study completion.
研究组 & 干预措施
PrimeC
Active Comparator
2 tablets of PrimeC administered twice daily (4 tablets a day), at a daily dose of 1496 mg
干预措施: PrimeC (Drug)
Placebo
Placebo Comparator
2 tablets of Placebo administered twice daily (4 tablets a day). Placebo tablets are matched in size, color and taste.
干预措施: Placebo (Drug)
结局指标
主要结局
Number of subjects who discontinued treatment prematurely
时间窗: 6 months
Number of subjects whose treatment is stopped prematurely for any reason
The mean difference between PrimeC and placebo in serum concentration of NDE PgJ2 at month 6
时间窗: 6 months
The mean difference between PrimeC and Placebo in serum concentration of NDE TDP-43 at month 6
时间窗: 6 months
Number of patients who discontinued treatment prematurely due to adverse events
时间窗: 6 months
Number of patients whose treatment is stopped prematurely specifically due to adverse events
Number of patients with clinically significant abnormal laboratory values
时间窗: 6 months
Incidence and severity of treatment-emergent adverse events (TEAEs)
时间窗: 6 months
Treatment emergent adverse event is any medical event associated with the drug
次要结局
- Change from baseline to 6 months in ALS functional rating scale - revised (ALSFRS-R)(6 months)
- Change from baseline to 6 months in slow vital capacity (SVC)(6 months)
- Change from baseline to 6 months in quality of life ALSSQOL-SF(6 months)
- Change from baseline to 6 months in PROMIS-10 quality of life questionnaire(6 months)
- Survival at 6 months of treatment(6 months)
- Composite survival at 6 months of treatment(6 months)
- Joint Assessment of Function and Survival after 6 months of treatment(6 months)
研究者
研究点 (4)
Loading locations...
相似试验
撤回
2 期
Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT00752999Rigel Pharmaceuticals
招募中
2 期
A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.Alzheimer DiseaseNCT06185543NeuroSense Therapeutics Ltd.20
已完成
2 期
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute SchizophreniaSchizophreniaNCT00905307Otsuka Pharmaceutical Development & Commercialization, Inc.459
撤回
2 期
IC14 for Treatment of Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisMotor Neuron DiseaseNCT03508453Implicit Bioscience
已完成
2 期
A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.Leukemia, Myeloid, AcuteNCT02450877Celgene7
相关资讯
NeuroSense's PrimeC Shows 33% Reduction in ALS Disease Progression in Phase 2b Trial- NeuroSense Therapeutics' PrimeC demonstrated a statistically significant 33% reduction in ALS disease progression (p=0.007) and 58% improvement in survival rates in its Phase 2b PARADIGM trial.
- The oral combination therapy showed differential expression of over 100 microRNAs, including downregulation of miR-199 and miR-181 associated with neuroinflammation and mortality.
- Despite promising clinical results, the company faces financial constraints with only $3.4 million in cash and is pursuing a critical partnership to fund Phase 3 trials beginning in late 2025.last yearNeuroSense Therapeutics Regains Nasdaq Compliance Amidst PrimeC Development for ALS- NeuroSense Therapeutics has regained compliance with Nasdaq's minimum equity requirement, ensuring its stock remains listed on the Nasdaq Capital Market.
- This milestone follows the company's successful efforts to bolster its financial position through new equity and reduced liabilities, exceeding the $2.5 million threshold.
- NeuroSense is advancing its lead drug candidate, PrimeC, towards a Phase 3 study for ALS, building on promising Phase 2b PARADIGM trial results.
- The company will be subject to a one-year monitoring period by Nasdaq to ensure continued compliance with equity requirements.last yearNeuroSense Therapeutics Presents PrimeC Data at ALS/MND Symposium- NeuroSense Therapeutics will present Phase 2b PARADIGM trial results of PrimeC, a potential ALS treatment, at the International Symposium on ALS/MND.
- Prof. Merit Cudkowicz will present the latest clinical outcomes from the PARADIGM trial, offering insights into PrimeC's potential to improve patient outcomes.
- Dr. Cristian Lunetta will share an in-depth biomarker analysis from the PARADIGM trial, providing critical insights into PrimeC's mechanism of action.
- The NeuroSense management team will attend, highlighting the company's commitment to advancing ALS research and neurodegenerative disease therapies.last yearNeuroSense Therapeutics to Discuss Phase 3 Trial of PrimeC for ALS with FDA- NeuroSense Therapeutics will meet with the FDA to discuss the Phase 3 trial design for PrimeC, an experimental therapy for amyotrophic lateral sclerosis (ALS).
- PrimeC, a combination of ciprofloxacin and celecoxib, aims to modulate inflammation, RNA processing, and iron accumulation, all disrupted in ALS.
- Phase 2b trial data showed PrimeC slowed disease progression by 36% and improved survival rates by 43% compared to placebo after one year.
- NeuroSense is also seeking early marketing approval for PrimeC in Canada, based on the Phase 2b PARADIGM trial results.last yearNeuroSense to Advance Phase 3 ALS Trial Following FDA Meeting- NeuroSense will meet with the FDA to finalize the Phase 3 trial design for PrimeC, a potential treatment for Amyotrophic Lateral Sclerosis (ALS).
- The meeting will focus on ensuring the trial design aligns with FDA requirements for a New Drug Application (NDA) submission.
- NeuroSense plans to submit its regulatory dossier to Health Canada in Q2 2025, with a decision expected by Q1 2026.
- PrimeC has demonstrated statistically significant reductions in disease progression and improved survival rates in clinical trials.last year
7 articles
1 / 2